EWTX: CIRRUS Paves the Way for a REMS-free Pan-HCM Medicine

Research evidence excerpt

EWTX: CIRRUS Paves the Way for a REMS-free Pan-HCM Medicine

reproduced, or distributed, in whole or in part, without the

prior written consent of Guggenheim. Without limiting the foregoing, the recipient is expressly prohibited from uploading, feeding, transmitting, or otherwise

providing this report or any related content to any internal or third-party artificial intelligence (“AI”) or machine learning system, including but not limited to

generative AI platforms, large language models, or similar technologies, without the prior written consent of Guggenheim.

Portions of the research contained herein have been generated using artificial intelligence ("AI"). We primarily use AI to gather general market or industry

data and to compile company-specific information to facilitate the recipient's preliminary review. In providing this research, we assume that any information

obtained from public sources, data suppliers (including AI systems) and other third parties is reasonable and reliable but acknowledge that any such

information (including AI content) could contain errors, inconsistencies, bias or outdated or irrelevant information. We seek to update our research as

appropriate, but various regulations may prevent us from doing so. Other than certain industry reports published on a periodic basis, the large majority of

reports are published at irregular intervals as appropriate in the research analyst's judgement. Guggenheim Securities conducts a full-service, integrated

investment banking and brokerage business. Guggenheim Securities is a member of SIPC (http://www.sipc.org). Guggenheim Securities' salespeople,

traders, and other professionals may provide oral or written market commentary or trading strategies to Guggenheim Securities' clients and our employees